The effect of sitagliptin on LV performance in diabetics

• Research type

  Research Study

• Full title

  The effect of sitagliptin on myocardial performance in patients with type 2 diabetes and coronary artery disease.

• IRAS ID

  22378

• Contact name

  David Dutka

• Eudract number

  2009-012776-27

• ISRCTN Number

  200901277627

• Research summary

  Glucagon-like peptide-1 (GLP-1) is a hormone which is secreted by cells in the gut in response to food. It acts to regulate glucose metabolism. GLP-1 has been shown to promote glucose uptake into heart muscle which can improve function. Sitagliptin (Januvia, MSD) inhibits the breakdown of a GLP-1 and is licensed for the treatment of type 2 diabetes. We are interested in finding out if sitagliptin can improve heart muscle performance in patients with type 2 diabetes.

• REC name

  East of England - Essex Research Ethics Committee

• REC reference

  09/H0301/47

• Date of REC Opinion

  14 Aug 2009

• REC opinion

  Further Information Favourable Opinion